Intellia Therapeutics, Inc. (NTLA)’in fiyatı nedir?

Intellia Therapeutics, Inc. (NTLA)’in fiyatı $13.15’dir

Intellia Therapeutics, Inc. (NTLA)’in piyasa değeri nedir?

Intellia Therapeutics, Inc. (NTLA)’in piyasa değeri $1.84B’dir.

Intellia Therapeutics, Inc. (NTLA) Fiyat Geçmişi

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Yıl	Performans
2026 (TTM)	45.98%
2025	-30.41%
2024	-56.69%
2023	-19.53%
2022	-67.57%
2021	120.71%
2020	225.24%
2019	10.28%
2018	-24.22%
2017	26.96%
2016	0.00%

Yıl

Performans

2026 (TTM)

45.98%

2025

-30.41%

2024

-56.69%

2023

-19.53%

2022

-67.57%

2021

120.71%

2020

225.24%

2019

10.28%

2018

-24.22%

2017

26.96%

2016

0.00%

Şirket	Hisse fiyatı	Değişim 1yıl%	Ülke
Vertex Pharmaceuticals Incorporated VRTX.US	$548.36	39.87%	US
Argenx SE ARGX.US	$1.06K	50.29%	NL
CSL Limited CSL.AX	$121.22	-12.71%	AU
Moderna, Inc. MRNA.US	$140.81	475.44%	US
Lonza Group AG LONN.SW	$765.25	7.74%	CH

Şirket

Hisse fiyatı

Değişim 1yıl%

Ülke